NO20054999L - Nye quinolin-, tetrahydroquinazolin- og pyrimidinderivater og fremgangsmater for behandling relatert til anvendelsen derav - Google Patents
Nye quinolin-, tetrahydroquinazolin- og pyrimidinderivater og fremgangsmater for behandling relatert til anvendelsen deravInfo
- Publication number
- NO20054999L NO20054999L NO20054999A NO20054999A NO20054999L NO 20054999 L NO20054999 L NO 20054999L NO 20054999 A NO20054999 A NO 20054999A NO 20054999 A NO20054999 A NO 20054999A NO 20054999 L NO20054999 L NO 20054999L
- Authority
- NO
- Norway
- Prior art keywords
- disorders
- tetrahydroquinazoline
- methods
- myocardial infarction
- pyrimidine derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45853003P | 2003-03-31 | 2003-03-31 | |
US49591103P | 2003-08-19 | 2003-08-19 | |
US51018603P | 2003-10-09 | 2003-10-09 | |
US53036003P | 2003-12-16 | 2003-12-16 | |
PCT/JP2004/004624 WO2004087669A1 (en) | 2003-03-31 | 2004-03-31 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20054999L true NO20054999L (no) | 2005-11-07 |
Family
ID=32854505
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20054999A NO20054999L (no) | 2003-03-31 | 2005-10-27 | Nye quinolin-, tetrahydroquinazolin- og pyrimidinderivater og fremgangsmater for behandling relatert til anvendelsen derav |
Country Status (13)
Country | Link |
---|---|
US (1) | US20050197350A1 (de) |
EP (1) | EP1464335A3 (de) |
JP (1) | JP2004300156A (de) |
KR (1) | KR20050118704A (de) |
AU (1) | AU2004226049A1 (de) |
BR (1) | BRPI0408910A (de) |
CA (1) | CA2518913A1 (de) |
HK (1) | HK1091488A1 (de) |
HR (1) | HRP20050780A2 (de) |
MX (1) | MXPA05010475A (de) |
NO (1) | NO20054999L (de) |
TW (1) | TW200508202A (de) |
WO (1) | WO2004087669A1 (de) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7378409B2 (en) | 2003-08-21 | 2008-05-27 | Bristol-Myers Squibb Company | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity |
EP1706384A1 (de) * | 2004-01-07 | 2006-10-04 | AstraZeneca AB | Therapeutische mittel i |
US7230002B2 (en) | 2004-02-03 | 2007-06-12 | Glenmark Pharmaceuticals Ltd. | Dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof |
WO2005075426A1 (en) * | 2004-02-03 | 2005-08-18 | Glenmark Pharmaceuticals Ltd. | Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof |
JP2007530445A (ja) * | 2004-03-30 | 2007-11-01 | 大正製薬株式会社 | ピリミジン誘導体及びその使用に関連する治療方法 |
WO2005110980A2 (en) | 2004-04-14 | 2005-11-24 | Amgen, Inc. | Aryl sulfones and uses related thereto |
WO2006011035A1 (en) * | 2004-07-23 | 2006-02-02 | Glenmark Pharmaceuticals Ltd. | Novel dipeptidyl peptidase iv inhibitors; process for their preparation and compositions containing them |
JP4959569B2 (ja) | 2004-10-12 | 2012-06-27 | グレンマーク・ファーマシューティカルズ・エスエー | 新規なジペプチジルペプチダーゼiv阻害剤、それらを含む医薬品組成物、およびそれらを調製するためのプロセス |
EP1831194A4 (de) * | 2004-12-21 | 2009-12-02 | Astrazeneca Ab | Heterocyclische mchr1-antagonisten und deren verwendung in der therapie |
WO2006138304A2 (en) * | 2005-06-14 | 2006-12-28 | Taigen Biotechnology | Pyrimidine compounds |
US8193206B2 (en) * | 2005-06-14 | 2012-06-05 | Taigen Biotechnology Co., Ltd. | Pyrimidine compounds |
EP1893244A4 (de) * | 2005-06-23 | 2009-06-24 | Univ Emory | Kontrastmittel |
WO2007001958A2 (en) * | 2005-06-23 | 2007-01-04 | Emory University | Stereoselective synthesis of amino acid analogs for tumor imaging |
JP2007091649A (ja) * | 2005-09-29 | 2007-04-12 | Taisho Pharmaceut Co Ltd | ピリミジン誘導体及びその使用に関連する治療方法 |
FR2902100A1 (fr) * | 2006-06-13 | 2007-12-14 | Sanofi Aventis Sa | Molecules duales contenant un derive peroxydique, leur synthese et leurs applications en therapeutique |
WO2008105968A1 (en) * | 2006-11-03 | 2008-09-04 | Smithkline Beecham Corporation | Novel seh inhibitors and their use |
US8450336B2 (en) | 2006-12-14 | 2013-05-28 | Nps Pharmaceuticals, Inc | Use of D-serine derivatives for the treatment of anxiety disorders |
KR101599661B1 (ko) * | 2007-05-17 | 2016-03-03 | 코텍스 파마슈티칼스, 인크. | 글루타메이트에 의한 시냅스 반응을 향상시키기 위한 이치환된 아미드 화합물 |
WO2009011336A1 (ja) * | 2007-07-18 | 2009-01-22 | Taisho Pharmaceutical Co., Ltd. | キノリン化合物 |
KR101546111B1 (ko) | 2007-10-11 | 2015-08-20 | 글락소스미스클라인 엘엘씨 | 신규한 sEH 억제제 및 그의 용도 |
JP5411867B2 (ja) | 2007-10-11 | 2014-02-12 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 新規sEH阻害剤およびそれらの使用 |
US8246752B2 (en) | 2008-01-25 | 2012-08-21 | Clear Catheter Systems, Inc. | Methods and devices to clear obstructions from medical tubes |
WO2009097474A1 (en) * | 2008-01-30 | 2009-08-06 | Smithkline Beecham Corporation | Novel seh inhibitors and their use |
WO2009097475A1 (en) * | 2008-01-30 | 2009-08-06 | Smithkline Beecham Corporation | NOVEL sEH INHIBITORS AND THEIR USE |
WO2009097476A1 (en) * | 2008-01-30 | 2009-08-06 | Smithkline Beecham Corporation | NOVEL sEH INHIBITORS AND THEIR USE |
US8273900B2 (en) * | 2008-08-07 | 2012-09-25 | Novartis Ag | Organic compounds |
US8461182B2 (en) * | 2008-10-02 | 2013-06-11 | Taisho Pharmaceutical Co., Ltd. | 7-piperidinoalkyl-3, 4-Dihydroquinolone derivative |
US20140113898A1 (en) * | 2010-11-08 | 2014-04-24 | Zalicus Pharmaceuticals Ltd. | Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers |
US9775843B2 (en) | 2012-10-11 | 2017-10-03 | Grünenthal GmbH | Treatment and/or prophylaxis of TSPO mediated diseases and/or disorders |
CN111757739A (zh) | 2017-12-13 | 2020-10-09 | 普拉西斯生物技术有限责任公司 | 整合应激反应路径抑制剂 |
BR112020019595A2 (pt) * | 2018-03-29 | 2021-01-05 | Takeda Pharmaceutical Company Limited | Composto, e, medicamento. |
WO2019236710A1 (en) | 2018-06-05 | 2019-12-12 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
AU2020209216A1 (en) | 2019-01-18 | 2021-08-26 | Astrazeneca Ab | PCSK9 inhibitors and methods of use thereof |
BR112021014514A2 (pt) * | 2019-02-25 | 2021-09-28 | Praxis Biotech LLC | Inibidores de via de resposta integrada ao estresse |
CA3142748A1 (en) | 2019-06-12 | 2020-12-17 | Praxis Biotech LLC | Modulators of integrated stress response pathway |
WO2021007487A1 (en) | 2019-07-11 | 2021-01-14 | Praxis Precision Medicines, Inc. | Formulations of t-type calcium channel modulators and methods of use thereof |
US10702525B1 (en) * | 2019-09-04 | 2020-07-07 | United Arab Emirates University | Pyrimidine derivatives as anti-diabetic agents |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI9300097B (en) * | 1992-02-27 | 2001-12-31 | Janssen Pharmaceutica Nv | (benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines |
DE4417163A1 (de) * | 1994-05-17 | 1995-11-23 | Hoechst Schering Agrevo Gmbh | Heterocyclylamino- und Heterocyclyloxy-cycloalkyl-Derivate, ihre Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide |
ES2237966T3 (es) * | 1998-08-20 | 2005-08-01 | Agouron Pharmaceuticals, Inc. | Agentes de gnrh no peptidicos, metodos y compuestos intermedios para su preparacion. |
US7101878B1 (en) * | 1998-08-20 | 2006-09-05 | Agouron Pharmaceuticals, Inc. | Non-peptide GNRH agents, methods and intermediates for their preparation |
CA2407149C (en) * | 2000-04-28 | 2010-10-12 | Takeda Chemical Industries, Ltd. | Melanin-concentrating hormone antagonist |
TW583185B (en) * | 2000-06-13 | 2004-04-11 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same |
JP4329290B2 (ja) * | 2000-10-06 | 2009-09-09 | 田辺三菱製薬株式会社 | 脂肪族含窒素五員環化合物 |
AU9419701A (en) * | 2000-10-06 | 2002-04-22 | Tanabe Seiyaku Co | Aliphatic nitrogenous five-membered ring compounds |
JP4329291B2 (ja) * | 2000-10-06 | 2009-09-09 | 田辺三菱製薬株式会社 | 含窒素五員環化合物 |
JP2004524295A (ja) * | 2001-01-26 | 2004-08-12 | スミスクライン・ビーチャム・コーポレイション | ウロテンシン−ii受容体アンタゴニスト |
BR0209932A (pt) * | 2001-05-22 | 2004-10-13 | Neurogen Corp | Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, preparação farmacêutica embalada, métodos para modular ligação de mch a um receptor de mch e de mvc, para alterar a atividade de transdução de sinal de um receptor de mch em uma célula, para tratar uma doença ou distúrbio associado com a ativação de receptor de mch patogênico obesidade e para determinar a presença ou ausência de receptor de mch em uma amostra, e, uso de um composto |
CN1582281A (zh) * | 2001-10-01 | 2005-02-16 | 大正制药株式会社 | Mch受体拮抗剂 |
IL160874A0 (en) * | 2001-10-22 | 2004-08-31 | Tanabe Seiyaku Co | 4-imidazolin-2-one derivatives |
US7012077B2 (en) * | 2001-12-20 | 2006-03-14 | Hoffmann-La Roche Inc. | Substituted cyclohexane derivatives |
WO2003070244A1 (en) * | 2002-02-22 | 2003-08-28 | Abbott Laboratories | Antagonist of melanin concentrating hormone and their uses |
SE0202134D0 (sv) * | 2002-07-08 | 2002-07-08 | Astrazeneca Ab | Therapeutic agents |
-
2004
- 2004-03-30 EP EP04007651A patent/EP1464335A3/de not_active Withdrawn
- 2004-03-30 US US10/812,075 patent/US20050197350A1/en not_active Abandoned
- 2004-03-31 WO PCT/JP2004/004624 patent/WO2004087669A1/en active Application Filing
- 2004-03-31 MX MXPA05010475A patent/MXPA05010475A/es not_active Application Discontinuation
- 2004-03-31 AU AU2004226049A patent/AU2004226049A1/en not_active Abandoned
- 2004-03-31 KR KR1020057018494A patent/KR20050118704A/ko not_active Application Discontinuation
- 2004-03-31 TW TW093108879A patent/TW200508202A/zh unknown
- 2004-03-31 JP JP2004107965A patent/JP2004300156A/ja active Pending
- 2004-03-31 BR BRPI0408910-3A patent/BRPI0408910A/pt not_active IP Right Cessation
- 2004-03-31 CA CA002518913A patent/CA2518913A1/en not_active Abandoned
-
2005
- 2005-09-06 HR HR20050780A patent/HRP20050780A2/xx not_active Application Discontinuation
- 2005-10-27 NO NO20054999A patent/NO20054999L/no not_active Application Discontinuation
-
2006
- 2006-11-02 HK HK06112084.6A patent/HK1091488A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2518913A1 (en) | 2004-10-14 |
MXPA05010475A (es) | 2006-05-25 |
AU2004226049A1 (en) | 2004-10-14 |
EP1464335A3 (de) | 2007-05-09 |
WO2004087669A1 (en) | 2004-10-14 |
EP1464335A2 (de) | 2004-10-06 |
TW200508202A (en) | 2005-03-01 |
KR20050118704A (ko) | 2005-12-19 |
HK1091488A1 (en) | 2007-01-19 |
US20050197350A1 (en) | 2005-09-08 |
HRP20050780A2 (en) | 2009-02-28 |
BRPI0408910A (pt) | 2006-03-21 |
JP2004300156A (ja) | 2004-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20054999L (no) | Nye quinolin-, tetrahydroquinazolin- og pyrimidinderivater og fremgangsmater for behandling relatert til anvendelsen derav | |
NO20064950L (no) | Pyrimidlnderivater og fremgangsmater for behandling basert pa anvendelse av disse | |
TW200626152A (en) | Pyridine derivatives and pharmaceutical compositions and uses thereof | |
US8343980B2 (en) | Quinazoles useful as modulators of ion channels | |
CN101903372B (zh) | 作为食欲肽受体拮抗剂的杂芳基衍生物 | |
JP5246499B2 (ja) | イソキサゾール誘導体及びその使用 | |
JP5857168B2 (ja) | ドーパミンd1リガンドとしての複素芳香族化合物およびその使用 | |
KR100932623B1 (ko) | 5-ht 수용기에서 활성을 갖는(3,4-다이하이드로-퀴나졸린-2-일)-(2-아릴옥시-에틸)-아민 | |
CY1114165T1 (el) | Παραγωγο 7-πιπεριδινοαλκυλ-3,4-διυδροκινολονης | |
ATE402935T1 (de) | Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen rezeptors zur behandlung von gastrointestinalen erkrankungen | |
HUE033441T2 (en) | 4- (Benzyl) piperazine-1-carboxylic acid phenylamide derivatives and related compounds as modulators of fatty acid hydrolase (phaha) for the treatment of anxiety, pain and other diseases | |
MY153719A (en) | Prokineticin 1 receptor antagonists | |
NO20072348L (no) | Thienopyridinone sammensetninger og fremgangsmate for behandling | |
Vasbinder et al. | Discovery and optimization of a novel series of potent mutant B-RafV600E selective kinase inhibitors | |
EA200970310A1 (ru) | Сульфонилпиразольные и сульфонилпиразолиновые производные карбоксамидина как антагонисты 5-ht | |
Tang et al. | Discovery of novel 7-azaindole derivatives bearing dihydropyridazine moiety as c-Met kinase inhibitors | |
MX2009005509A (es) | 2-aminoquinolina como los antagonistas de los receptores 5-hidroxitriptamina 5a (5-ht5a). | |
DE602006009804D1 (de) | Piperidin-4-yl-amidderivate und ihre verwendung als antagonisten des sst-rezeptors vom subtyp 5 | |
DE502004011551D1 (de) | 1,3,4-substituierte pyrazole als 5-ht rezeptor-antagonisten zur behandlung von psychosen und neurologischen störungen | |
MX2010009643A (es) | Derivados de 2-aminoquinolina como antagonistas del receptor 5-hidroxitriptamina (5a). | |
NO20092688L (no) | Forbindelser med en kombinasjon av cannabinoid-CB1 antagonisme og acetylcholinesteraseinhibering | |
Gomółka et al. | Novel 4-aryl-pyrido [1, 2-c] pyrimidines with dual SSRI and 5-HT1A activity. Part 5 | |
CA2829171A1 (en) | Pyrazolidin-3-one derivatives | |
WO2007069671A1 (ja) | 二環式複素環化合物 | |
ATE472538T1 (de) | 8-alk0xy-4-methyl-3, 4-dihydr0-chinaz0lin-2-yl- amine und ihre verwendung als 5-ht5a-rezeptor- liganden |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |